Drug Trial Radar · NCT03955380
MAD Phase I Study to Investigate Contraloid Acetate
Last checked: Nov 19, 2026Latest source record: May 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Dec 12, 2018
Primary completion
Apr 3, 2019
Study completion Apr 3, 2019
Sponsor
- Lead sponsor
- Prof. Dr. Dieter WillboldAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Helmholtz-Gemeinschaft Deutscher Forschungszentren, Germany; Medical University of Vienna; NeuroScios, Austria; Nuvisan, Germany; Fundación Teófilo Hernando, Spain; Alzheimer's Association
- First posted
- May 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, alias PRI-002) is an orally available all-D-peptide, which was developed to directly destroy toxic and replicating A-beta oligomer prions, by disassembling them into A-beta monomers. The study drug is specifically designed for the curative or at least disease-modifying treatment of cognition, memory and behavior deficits in Alzheimer´s disease patients. The study drug is BBB penetrable \[1\] and has demonstrated target engagement in vitro and in vivo \[2, 3\]. Treatments in three different transgenic mouse models in three different laboratories yielded improved cognition and deceleration of neurodegeneration, even under truly non-preventive treatment conditions and even when applied orally \[2-5\]. The hereby obtained PRI-002 plasma levels have also been achieved in humans after single oral dosing.
Conditions
- Alzheimer Dementia
- Alzheimer Disease
Interventions
ContraloidDrug
Oral administration of capsules, drug substance or placebo without any exipients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of safety and tolerability of Contraloid by monitoring vital signs, ECG and lab valuesTime frame: 21 days for cohort 1 and 35 days for cohort 2
- Assessment of pharmacokinetics of Contraloid: Area under curve (AUC) in plasmaTime frame: 168 hours
- Assessment of pharmacokinetics of Contraloid: Cmax in plasmaTime frame: 21/35 days
- Assessment of pharmacokinetics of Contraloid: Tmax in plasmaTime frame: 21/35 days
- Assessment of pharmacokinetics of Contraloid: Terminal elimination half-life (t1/2) in plasmaTime frame: 21/35 days
- Assessment of pharmacokinetics of Contraloid: distributive half-life (t1/2alpha) in plasmaTime frame: 21/35 days
- Assessment of pharmacokinetics of Contraloid: terminal elimination half-life (t1/2beta) in plasmaTime frame: 21/35 days
- Assessment of pharmacokinetics of Contraloid: Elimination Constant (Kel alpha) in plasmaTime frame: 21/35 days
- Assessment of pharmacokinetics of Contraloid: Elimination Constant (Kel beta) in plasmaTime frame: 21/35 days
- AUC0-24 of Contraloid does not exceed of 2.3 µg·h/mLTime frame: 21/35 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Forschungszentrum Jülich
Jülich, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.